IgA nephropathy laboratory findings

IgA nephropathy Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating IgA nephropathy from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
IgA nephropathy laboratory findings On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of IgA nephropathy laboratory findings All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on IgA nephropathy laboratory findings
CDC on IgA nephropathy laboratory findings
IgA nephropathy laboratory findings in the news
Blogs on IgA nephropathy laboratory findings
Directions to Hospitals Treating IgA nephropathy
Risk calculators and risk factors for IgA nephropathy laboratory findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

• There are no specific and sensitive diagnostic laboratory findings associated with IgA nephropathy.

Laboratory Findings

• There are no specific and sensitive diagnostic laboratory findings associated with IgA nephropathy.
• Some patients with IgA nephropathy may have elevated concentration of serum total IgA.
  • There is not enough evidence of serum total IgA concentration for the measurement of the severity or activity of IgA nephropathy.
• The urinary Immunoglobulins are not distinctive in IgA nephropathy.

Initial Evaluation

• Assess all patients with biopsy-proven IgA nephropathy for secondary causes to rule out common causes of secondary IgA nephropathy
  • Viral serologies:
    • HIV, HBV, HCV
  • Liver function tests
  • Electrophoresis of serum immunoglobulins
• Assess the risk of progression and prognosis by the following parameters at diagnosis and at follow-up:
  • Blood pressure measurement
  • Serum creatinine to estimate glomerular filtration rate (GFR)
  • Proteinuria
  • Pathological features
• A kidney biopsy is to be considered only if signs of AKI and macroscopic hematuria persist for at least 5 days since the onset of kidney injury.